<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026528</url>
  </required_header>
  <id_info>
    <org_study_id>Bra liv med diabetes typ 2</org_study_id>
    <nct_id>NCT05026528</nct_id>
  </id_info>
  <brief_title>Randomized Controlled Trial of Digital Diabetes Self Management Education and Support for Patients With Type 2 Diabetes</brief_title>
  <official_title>Randomized Controlled Trial of a Digital Diabetes Self Management Education and Support System for Patients With Type 2 Diabetes in Primary Health Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Jönköping County</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Östergötland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Swedish Diabetes Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council of Southeast Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Jönköping County</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effect of using a digital diabetes self management&#xD;
      education and support system compared with standard care for patients with type 2 diabetes in&#xD;
      primary health care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed verbally and in text participants will sign a consent to participate.&#xD;
      The participant will then be randomized to either use a digital diabetes self management&#xD;
      education and support system for 10 weeks together with a diabetes nurse, or to continue with&#xD;
      the regular care. The effects will be evaluated after 6, 12 and 36 months from randomization&#xD;
      with emphasis on cardiovascular risk factors, life-style, diabetes knowledge and health&#xD;
      economics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
    <masking_description>The investigator performing measurements and collecting data as well as the outcomes assessor will be blinded to group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>The level of glycated hemoglobin A1 in blood measured in mmol/mol.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Plasma cholesterol</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma LDL-cholesterol</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Plasma HDL-cholesterol</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma triglycerides</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mmol/L</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinary albumin/creatinine ratio</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>mg/mmol</description>
  </other_outcome>
  <other_outcome>
    <measure>Waist circumference</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>cm</description>
  </other_outcome>
  <other_outcome>
    <measure>Body mass index</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>kg/m2</description>
  </other_outcome>
  <other_outcome>
    <measure>Self reported physical activity level</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>International Physical Activity Questionnaire (IPAQ)</description>
  </other_outcome>
  <other_outcome>
    <measure>Objectively measured physical activity level</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Accelerometer Axivity AX3 will be used on a subgroup of 100 participants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Self reported dietary intake</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Indicator questions from the Swedish National Board of Health and Welfare</description>
  </other_outcome>
  <other_outcome>
    <measure>Health literacy</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>HLS-EU-Q16 questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient-reported outcome and experience measures</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Questionnaire developed and validated by the National Swedish Diabetes Registry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Digital DSME/S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ten-week intervention during which the participant uses a digital diabetes self management education and support system together with the diabetes nurse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group continuing with regular standardized care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Digital diabetes self management education and support system</intervention_name>
    <description>Digital diabetes self management and support system</description>
    <arm_group_label>Digital DSME/S</arm_group_label>
    <other_name>Live well with type 2 diabetes</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus diagnosed according to WHO criteria &lt; 5 years from&#xD;
             randomization:&#xD;
&#xD;
          -  Fasting plasma glucose &gt; 7 mmol/L at two timepoints. OR&#xD;
&#xD;
          -  HbA1c ≥ 48 mmol/mol twice or in combination with fasting plasma glucose &gt; 7 mmo/L&#xD;
             once. OR&#xD;
&#xD;
          -  Non-fasting plasma glucose ≥ 11.1 mmol/L at one timepoint in combination with symptoms&#xD;
             of hyperglycemia.&#xD;
&#xD;
          -  Access to a digital ID-card to access the digital system&#xD;
&#xD;
          -  Access to a computer, tablet or smart phone&#xD;
&#xD;
          -  Sufficient knowledge of written and spoken Swedish to understand the information given&#xD;
             in the digital system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with Insulin&#xD;
&#xD;
          -  Other co-morbidities limiting the use of the digital system according to the diabetes&#xD;
             nurse judgement. E.g. dementia or severe psychiatric disease.&#xD;
&#xD;
          -  Other forms of diabetes mellitus than type 2 diabetes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Stomby, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Region Jönköping County and Linköping University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Stomby, MD/PhD</last_name>
    <phone>0046739595129</phone>
    <email>andreas.stomby@rjl.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frida Jarl, MD</last_name>
    <email>frida.jarl@rjl.se</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mHealth</keyword>
  <keyword>Primary health care</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Since it is unclear to what extent this form of personal information can be transferred abroad according to Swedish law, both within and outside the European Union we do not plan to share individual patient data at the moment.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

